A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Noneclear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Inkeun | - |
dc.contributor.author | Lee, Se Hoon | - |
dc.contributor.author | Lee, Jae Lyun | - |
dc.date.available | 2020-02-27T09:40:45Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2018-10 | - |
dc.identifier.issn | 1558-7673 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/3243 | - |
dc.description.abstract | We conducted a multicenter phase II trial of axitinib for patients with advanced noneclear-cell renal cell carcinoma who had failed prior treatment with temsirolimus. Axitinib showed promising efficacy in terms of objective response rate and progression-free survival in recurrent or metastatic noneclear-cell renal cell carcinoma when used after failure with temsirolimus. Background: The optimal treatment option for noneclear-cell renal cell carcinoma (nccRCC) is not established. We conducted a multicenter phase II trial of axitinib for patients with advanced nccRCC who had failed prior treatment with temsirolimus. Patients and Methods: Patients with histologically confirmed metastatic or recurrent nccRCC received 5 mg axitinib twice daily. Prior use of vascular endothelial growth factor pathway inhibitors was not allowed. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were objective response rate (ORR), disease control rate, overall survival, and safety. Results: Forty patients were included between January 2013 and December 2016. The median age was 59 years (range, 22-84 years). Eastern Cooperative Oncology Group performance status were 0 (7.5%) and 1 (92.5%), and 82.5% of patients had undergone prior nephrectomy. Papillary type 2 (60.0%) was the most common histology, and patients belonged to favorable (12.5%), intermediate (72.5%), and poor (15.0%) risk groups according to the International Metastatic Renal Cell Carcinoma Database Consortium risk stratification. With a median follow-up duration of 14.7 months (95% confidence interval, [ CI], 10.8-18.6 months), the median PFS was 7.4 months (95% CI, 5.2-9.5 months). The ORR was 37.5%, and the disease control rate was 67.5%. The median overall survival was 12.1 months (95% CI, 6.4-17.7 months). Most adverse events were manageable, and no unexpected toxicities were found. Conclusion: Axitinib showed promising efficacy in terms of ORR and PFS in recurrent or metastatic nccRCC when used after failure with temsirolimus. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | CIG MEDIA GROUP, LP | - |
dc.relation.isPartOf | CLINICAL GENITOURINARY CANCER | - |
dc.subject | INTERFERON-ALPHA | - |
dc.subject | OPEN-LABEL | - |
dc.subject | SUNITINIB | - |
dc.subject | EVEROLIMUS | - |
dc.subject | PAZOPANIB | - |
dc.subject | SORAFENIB | - |
dc.subject | NIVOLUMAB | - |
dc.title | A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Noneclear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000446339100006 | - |
dc.identifier.doi | 10.1016/j.clgc.2018.05.011 | - |
dc.identifier.bibliographicCitation | CLINICAL GENITOURINARY CANCER, v.16, no.5, pp.E997 - E1002 | - |
dc.identifier.scopusid | 2-s2.0-85048584377 | - |
dc.citation.endPage | E1002 | - |
dc.citation.startPage | E997 | - |
dc.citation.title | CLINICAL GENITOURINARY CANCER | - |
dc.citation.volume | 16 | - |
dc.citation.number | 5 | - |
dc.contributor.affiliatedAuthor | Park, Inkeun | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Metastasis | - |
dc.subject.keywordAuthor | MiT family translocation tumor | - |
dc.subject.keywordAuthor | Papillary renal cell carcinoma | - |
dc.subject.keywordAuthor | Temsirolimus | - |
dc.subject.keywordAuthor | VEGFR TKI | - |
dc.subject.keywordPlus | INTERFERON-ALPHA | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | SUNITINIB | - |
dc.subject.keywordPlus | EVEROLIMUS | - |
dc.subject.keywordPlus | PAZOPANIB | - |
dc.subject.keywordPlus | SORAFENIB | - |
dc.subject.keywordPlus | NIVOLUMAB | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Urology & Nephrology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Urology & Nephrology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.